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This article covers the scientific highlights of the
MDRF-ADA Postgraduate Course in Diabetology,
which was held first time in India, at Chennai during
20-22 September, 2002. Topics presented at the
course included prevention of diabetes, management
of diabetes and its  complications like diabetic
nephropathy, ret inopathy and neuropathy,
management of associated comorbities like obesity
and hypertension, pregnancy in diabetic women,
newer insulin delivery systems, insulin regimens, oral
hypoglycemic agents, current and future trends in
self monitoring of blood glucose, developing
standards for diabetic education and optimal
strategies for delivering effective self management
education.
In the opening lecture of the course, Dr. Aaron
Vinik (Eastern Virginia Medical School, Virginia,
U.S.A), spoke on “Prevention of Diabetes”. He stated
that diabetes had become  a global problem. In 1997,
2.1% of world population or 124 million people had
diabetes (Type 1 and Type 2).  Of these 97% or 120
million people world-wide had Type 2 diabetes.
Approximately 1% more were added each year to
the existing diabetic population. The natural history
of Type 2 diabetes is progression from normal
glucose tolerance to impaired glucose tolerance
(IGT) to diabetes. Thus the right time for prevention
is to intervene at the IGT stage before the beta cell
decompensation starts.  UKPDS has also proved that
beta cell function starts deteriorating approximately
a decade prior to diagnosis of diabetes and at the
time of diagnosis approximately 50% of the beta cell
function is already lost.  Type 2 diabetes is the result
of deteriorating beta cell function with increasing
insulin resistance (reducing insulin sensitivity). Insulin
resistance can be broadly governed by inherited and
acquired influences like obesity, aging, glucotoxicity,
lipotoxicity and smoking.
The results of Nurses Health Study have shown
that even among overweight and obese individuals,
the combination of an appropriate diet, a moderate
amount of exercise, abstinence from smoking and
reduced alcohol consumption can substantially lower
the risk of Type 2 diabetes.
Even modest weight loss has shown the benefits
like lowering of lipids, better glycemic control and
reduced prevalence of coronary artery disease.  The
Finnish Diabetes Prevention Program showed that
lifestyle interventions (diet and exercise) in IGT
patients reduced the relative risk of diabetes
development by 58%.  Conversely, a mere 3% weight
gain increases the chances to get diabetes in IGT
individuals by 81%.
In the Diabetes Prevention Program done in USA
on patients with IGT with diet (reduced calorie with
25% fat) aimed for 7% weight loss, exercise (30 min/
day, 5 days a week) or metformin (850mg twice daily)
showed that life style modifications (diet and
exercise) reduced development  of diabetes by 58%
but metformin reduced the development by 31%. It
has been observed that strength training may serve
as an valuable adjunct to aerobic training.  Newer
evidence suggests that long bouts of exercise have
greater effects over weight loss in comparison to
short bouts.
Several studies are currently assessing the role
of pharmacological intervention to prevent diabetes
in individuals with IGT. The current recommendations
to prevent or delay diabetes are:
a. Individuals at high risk should be made aware of
benefits of modest weight loss and regular
physical activity.
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b. Dietary modifications with moderate calorie diet, high
intake of cereal fiber and polyunsaturated fatty acids,
low intake of transfatty acids and intake of low
glycemic index foods should be preferred.
c. Anti-obesity drugs can be started in severely obese
patients.
d. While treating the patients for diabetes and
associated co morbidities search should be made
for alternative drugs that do not promote weight gain.
e. Smoking should be totally stopped and only modest
amount of alcohol intake should be allowed, if any.
Dr. F. Xavier Pi-Sunyer, (St. Lukes –Roosevelt
Hospital, New York, U.S.A.), discussed the hormonal
regulation of body weight.  He showed evidence that
the body weight is controlled by energy balance
equation, whereby energy intake equals energy
expenditure when body weight is stable.  When the
body weight is lowered, the regulatory mechanisms
which increase the body weight are increased
hunger, decreased activity level, high lipoprotein
lipase activity and increased insulin sensitivity acting
together to increase the body weight. The regulatory
mechanisms for increasing weight are better than
mechanisms for lowering weight. Increased BMR,
increased satiety, increased insulin resistance and
increased adipocyte size are some of the
mechanisms to decrease body weight.  The
peripheral signals that are important to energy
balance are the gut peptides, the pancreatic
hormones, the peptidases secreted from the adipose
tissue and neurotransmitters.
Long term food regulation depends on insulin,
leptin and fuel molecules. Increase in adipocyte mass
increases leptin (produced by leptin genes) which
block hypothalamic receptor and results in reduced
food intake and increased thermogenesis. It has
ability to cross the blood brain barrier and is known
as leptin regulatory system. The effect of leptin is to
reduce body weight, food intake, insulin secretion,
blood glucose and to activate sympathetic system.
Thus lept in def ic iency may lead to obesity,
hyperphagia, hyperinsulinemia, insulin resistance,
diabetes mellitus and autonomic imbalance. Leptin
resistance has been documented in obese persons.
Dr. Francine Kaufman,  (USC School of
Medicine, Los Angeles, USA), presented about the
newer insulin delivery systems to improve diabetes
outcome in patients with Type 1 diabetes.  A number
of novel insulin delivery devices like insulin pens,
inhaler insulin and continuous subcutaneous insulin
infusion have been developed. Insulin pens have
been successfully used for almost 2 decades.  They
are convenient and cause less pain in comparison
to conventional injections. The inhaled insulin has
also being widely used in Type 1 diabetic patients.
3gm of inhaled insulin roughly equals to 10 units of
subcutaneous insulin.  The inhaled insulin can also
be used in basal bolus regimen – as inhaled insulin
can be used as bolus, while injectable insulin could
be used as basal insulin. With the availability of short
acting (lispro / aspart) and long acting (glargine)
insulin analogues, the basal bolus regimen has
become more effective and can offer a good measure
to control the wider fluctuations in Type 1 diabetic
patients. Insulin pump therapy has been widely used
since two decades and its use is increasing day by
day.  It has also been used in children of 1 year of
age.  The use of continuous subcutaneous insulin
infusion pump only at night time in Type 1 diabetic
patients has also been shown to have decreased
evidence of hypoglycemia and a better fasting
plasma glucose levels.
The glucose monitoring systems like Glucowatch
biographer and Continuous Glucose Monitoring
Systems (CGMS) are now being widely used and
they offer a good way to monitor glycemic status of
Type 1 diabetic patients.  The evolving options could
be implantable sensors and pumps and we could
thus hope to have a much better monitoring systems
in near future.
Dr. Lois Jovanovic, (Sansum Medical Research
Inst i tute, Cal i fornia, U.S.A.),  spoke about
management of pregnancy in diabetic women.  She
classified the diabetes in pregnant women in two
classes:
A. Normoglycemic / Optimal Control.
a. Fasting 55 – 65 mg%
b. 1 hour post meal <140mg%
c. Mean glucose of 84 mg%
B. Less than Optimal Control : blood glucose
documented outside of normal range.
Prior to 1922, no infant of a diabetic mother
survived. With the advent of insulin and optimally
controlling mean maternal blood glucose levels, the
infant mortality rate decreased nearer and nearer to
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that seen in the general population. The measures
by which this glycemic control has been achieved
are diet, insulin, moderate exercises and frequently
monitored blood glucose.
Diet is the main stay of therapy for pregnant
diabetic women. The diet plan that has been
successful is a diet that is calculated as 30 Kcal /kg/
day in a normal weight woman and 25 kcal/kg/day in
an overweight woman with expectations to maintain
the body weight around ideal body weight. The
caloric requirement from carbohydrate should be
around 40% to 60% of the diet.
The normoglycemia or optimal control could only
be achieved with 3-4 insulin injections /day. The
insulin dose is calculated as 0.7 units/kg/day for the
first trimester, 0.8 units / kg/day for the second
trimester and 0.9 units  per kg/day in the third
trimester.  The insulin requirement at term is 1.0 unit
/ kg/day. The total daily dose is divided in half to be
delivered as the basal insulin and rest to the meal
related insul in (boluses) needs. The use of
continuous subcutaneous insulin infusion (CSII) has
revolutionized the glycemic control, but multiple
insulin injection can also simulate the CSII pump. In
monitoring of glycemic control, it must be kept in mind
that HbA1c is 20% lower in pregnant women in
comparison to non-pregnant women.
Animal studies have shown that hyperglycemia
during first trimester causes dys-organogenesis.
Caudal agenesis / absent lower spine is pathognomic
of diabetes. The hyperinsul inemia and
hyperglycemia of pregnancy leads to adiposity or big
bad baby syndrome which could be prevented by
normoglycemia.  Results of Diabetes in Early
Pregnancy (DIEP) Trial have shown that earlier the
diabet ic pregnant women starts achieving
normoglycemia, the less is the chance of fetal
malformations. The diabetic women with well-
controlled HbA1c have shown normal rate of abortion
like general population, but those with HbA1c >7%
have shown increased incidence of spontaneous
abortions.
In pregnancy associated with nephropathy if the
serum creatinine is <2mg%, the outcome is good,
while serum creatinine of >2 mg% is compounded
with hypertension and proteinuria. Rapid
normalization of maternal blood glucose may lead
to diabetic retinopathy. In DIEP trial, it has been
shown that the first trimester retina status guides
towards the risk of progression of retinopathy. The
group with a higher HbA1c and worst retina at first
trimester progressed very faster than group with
same HbA1c with better retina at first trimester. The
DIEP trial has also shown that progression of diabetic
retinopathy is independent of glycemic control in
pregnancy but the eye needs frequent monitoring.
Better glycemic control has also been shown to
reduce the prevalence of caesarian sections in
pregnant diabetic women. If the baby is normal and
the glycemic control is good, there is no need to
initiate the pregnancy. Initiation should be planned
if the fetus is endangered.
Hypoglycemia is an associated outcome of insulin
therapy.  But hypoglycemia has not been associated
with adverse outcome in diabetic pregnancy in
humans. Oral hypoglycemic agents have not been
recommended in diabetic pregnancy as their safety
is yet not proven. Only human insulin has been
approved  by the FDA for use in pregnancy. Thus
with normalization of maternal blood glucose, the
pregnancy outcome could be near normal in a
pregnant diabetic women like non-diabetic women,
but large clinical trials are necessary.
Dr. Martha M. Funnell, (Michigan Diabetes
Research and Training Centre, Michigan, U.S.A.)
discussed about “Developing standards for diabetic
education”.  Diabetes self management education
is the corner stone of care for all persons with
diabetes. The development of standards helps to
define quality so that diabetes self management
education can be implemented to diverse settings
and facilitate improvement in health outcomes.
Standards need to be evidence-based, clearly
defined, and broad enough to adapt the new trends
and changes in the delivery of diabetes care and
the health care systems.  Standards typically include
criteria related to program structure, the educational
process including the curriculum and outcome
measures. Incorporating recommendations about
program organization and operation helps to promote
institutional support.
While standards help to ensure consistency in
process and outcomes, they are not meant to mandate
a particular program or methodology. In order to be
meaningful, outcome measures need to be selected
that will best match the goals and objectives of the
program and the patient population and include
behavioral psychosocial and metabolic measures.
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Dr. John Buse (University of North Carolina,
U.S.A.) discussed about  Oral agents. When and
How to use them in type 2 diabetes. The basic
pathophysiology of Type 2 diabetes mellitus is
defective insulin secretion and insulin sensitivity. The
measures which improve the insulin secretion are
sulphonylureas and glinides while measures
improving insulin sensitivity are diet, exercise,
glitazones and metformin. The ADA recommends
premeal plasma glucose between 90-130mg% and
HbA1c of <7% while they have not recommended
any glycemic range for post prandial glucose. The
American College of Endocrinology recommends
premeal plasma glucose value of <110 mg%, 2 hour
postprandial plasma value of <140mg% and a HbA1c
value of <6.5%. DCCT and UKPDS trials have clearly
shown the benefits of intensive diabetes therapy in
reducing complications. Thus it is mandatory now to
maintain stringent glycemic control.
The treatment of Type 2 diabetes should be
targeted to the pathophysiology of Type 2 diabetes
namely increased insulin resistance and reduced
insulin  secretion leading to hyperglycemia in diabetic
state by causing increase hepatic glucose
production, increase glucose absorption from the
intestine, decreased insulin secretion by pancreas
and reduced peripheral glucose uptake in adipose
tissue and muscles. The drugs which reduces the
hepatic glucose output are biguanides and
thiazolidinediones. The drugs which increases insulin
secretion from pancreas are sulphonylureas and
glinides (repaglinide, nateglinide). The drugs
reducing the glucose absorption from the intestine
are alpha-glucosidase inhibitors (acarbose and
miglitol).  Drugs that increase the peripheral glucose
uptake at the level of muscles and adipose tissue
are thiazol idinediones (piogl i tazone and
rosiglitazone) and biguanides.
The combination therapy should be planned if
monotherapy fails or to counter insulin resistance
as well as to increase insulin secretion.  The fasting
and the preprandial glucose levels could be
controlled by reducing hepatic glucose output (by
metformin), increasing insul in sensit iv i ty by
glitazones or increasing insulin availability (by
sulphonylurea / glinides). The postprandial blood
glucose can be controlled by reducing carbohydrate
absorption rate (by alpha-glucosidase inhibitors) by
reducing carbohydrate intake or rapidly increasing
insulin availability with meals (by glinides).
It is important to note that the commonly used
oral hypoglycemic agents may produce some side
effects.  The common side effects of sulphonylureas
and glinides are hypoglycemia and weight gain.
Biguanides may not cause weight gain but it causes
gastrointest inal  (GI) upset and they are
contraindicated in renal, cardiac and hepatic
insufficiency (as they can induce lactic acidosis
under these situations).  Alpha-glucosidase inhibitors
may cause GI upset and flatulence but they have a
rare r isk of l iver enzyme elevat ion also.
Thiazolidinedione may cause edema, weight gain,
anemia and rarely cardiac failure.
In her second lecture, Dr. Francine Kauffman,
discussed about the “Treatment of childhood and
adolescent Type 2 diabetes mellitus”. 25% of new
Type 2 diabetes mellitus cases in the US now belong
to this category. The predisposing risk factors for
childhood diabetes are obesity, sedentry life style,
puberty, genetic defects and gender (girls > boys).
There is evidence that breast feeding exclusively
upto 6 months and in total upto 12 months prevents
obesity.  84% of obesity is due to eating habit with
>30% calorie coming from fat. Children of obese
parents are 5 times more at risk to be obese.
Puberty is associated with insulin resistance.
Lower insulin stimulated glucose disposal has been
seen at puberty due to growth hormone and insulin
like growth factors. The obesity may be due to
increased fat consumption and meal size. As normal
pubertal transition has been associated with insulin
resistance, healthy beta cells adapt to this, but the
failure to adapt this situation results in Type 2
diabetes mellitus in children. The development of
Type 2 diabetes mellitus is faster in children in
comparison to parents. Presenting symptoms could
be weight loss, ketosis, high HbA1c, ketoacidosis,
acanthosis nigricans and some may have circulating
antibodies like GAD and ICA. The children at risk
are those with BMI > 85th percentile, a diabetic
relative, ethnic group with high diabetes prevalence
and children with signs of insulin resistance like
dyslipidemia, acanthosis nigricans, hypertension and
polycystic ovarian syndrome. A child with any of the
above symptoms with age of ≥  than 10 years should
be screened.
Non-pharmacological treatment modalit ies
include child education, family education about
diabetes and nutrition and proper exercises as they
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benefit the child by decreasing the weight gain
velocity. HbA1c should be kept below 7.0%.  The drugs
of choice to control blood glucose are insulin, insulin
analogue, sulphonylurea and metformin. The anti-
obesity drugs sibutramine and orlistat are not
recommended by FDA for pediatric population.  Less
than 10% of patients are controlled by diet and
exercise while others require oral agents or
combination therapy with SU and metformin.
Co-morbidities associated with adolescent Type
2 diabetes mellitus are hypertension (17-32%), high
lipid levels (4-32%), sleep apnea syndrome,
depression and dyslipidemia. Prediabetes has also
been seen in children. In U.S.A. 20-25% obese
adolescents have IGT. As obesity is associated with
diabetes, a term diabesity has been suggested.  The
diabesity prevention strategy should be planned.
Schools should be the target with promotion of
physical activity, supply of better nutritious food and
advise to reduce obesity.
Dr. Claude L.Cowan (George University Medical
Centre, Washington, U.S.A) spoke about the
“Pathogenesis and management of diabet ic
retinopathy”.  Diabetic retinopathy is a clinical
manifestat ion of a progressive ret inal
microangiopathy, characterized by a combination of
vascular incompetence (localized and diffuse retinal
thickening) and vascular insufficiency (localized and
diffuse non-perfusion/proliferative retinopathy).
Diabetic retinopathy is a major cause of visual
morbidity and is highly correlated with duration of
diabetes, glycemic control and BP control.
Disordered glucose metabol ism is the
biochemical abnormality associated with diabetes.
Persistent hyperglycemia precipitates alterations to
blood vessel walls and the cellular components of
the blood. Probable pathogenic mechanisms are
sorbitol pathway, hemodynamic and rheologic
abnormalities, advanced glycosylation end products
and vasoact ive factors l ike VEGF (vascular
endothelial growth factors). Persistent hyperglycemia
induces a procoagulant state and provides
biochemical changes which al ter vascular
permeability. Expression of vasopermeability and
vasoproliferative factors is linked to the severity and
duration of disordered glucose metabolism, as is the
risk for  retinopathy.
Non prol i ferat ive diabet ic ret inopathy is
manifested cl inical ly by the presence of
microanuerysms, hemorrhage, lipid exudates, retinal
edema, cotton wool spots, venous beading or loops
and I .R.M.A. ( intraret inal  microvascular
abnormalities). Proliferative retinopathy develops
when retinal ischemia associated with capillary non-
perfusion induces the proliferation of newly formed
blood vessels over the surface of the retina or optic
nerve. The predictors for progression of NPDR (non
prol i ferat ive diabet ic ret inopathy) to PDR
(proliferative diabetic retinopathy) are venous
beading, intra retinal microvascular abnormalities,
severe retinal hemorrhage and cotton wool spots.
Vitreous hemorrhages occur when the fibrovascular
tissues, exposed to tractional forces associated with
contraction of the posterior vitreous, ruptures.
Traction detachment of the retina may accompany
the vi treous hemorrhage or may occur
independently.
The management of diabetic retinopathy depends
on better glycemic control, management of other
vascular disorders, periodic screening for
retinopathy, timely laser photocoagulation and
vitrectomy. Thus blindness from diabetes is largely
preventable.  Better glycemic control and laser
therapy significantly reduces the risk for vision loss.
The promise of new therapies should not
overshadow the effectiveness of current approaches
to the prevention of diabetic blindness.
In his second lecture, Dr. Aaron Vinik, discussed
on pathogenesis and management of diabetic
neuropathy. Diabetic neuropathies are a family of
diseases, encompassing a wide range of abnormalities
that affects the peripheral nerves.  It is the most common
peripheral neuropathy resulting in 50-70% of non-
traumatic amputations.  It can be classified as focal and
diffuse.  Focal neuropathy involves the single nerves
(mononeuritis) and should be differentiated from
entrapment neuropathies.  Diffuse diabetic neuropathy
can be further subdivided into proximal and distal type.
Distal symmetrical mixed sensori motor polyneuropathy
is the most common type of neuropathy found in
diabetics and it can involve both small and large fibers.
Small fiber involvement manifests as pain, hyperalgesia,
loss of thermal sensitivity, reduced light touch and pin
prick sensation. Large fiber neuropathy manifests as
reduced vibration and position sense, weakness,
muscle wasting and depressed tendon reflexes.
Autonomic neuropathy is another form of diffuse
neuropathy that occurs mostly in Type 1 patients,
resulting mainly from the small fibre involvement,
affecting almost every system of the body from
cardiovascular to genitourinary.
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Treatment of diabetic neuropathy is based on
better glycemic control and symptomatic treatment
for pain and other associated symptoms like
numbness, postural hypotension and erectile
dysfunction. Strengthening exercises for muscle are
of great help. The future strategies for treating
diabetic neuropathies could be aldose reductase
inhibitors  and PKC inhibitors like LY333531 which
will act at the pathogenic mechanisms causing
neuropathy. There are several agents like GLA
(gamma linolenic acid) and ALA (alpha lipoic acid)
which have shown impressive effects on nerve
function. We can hope that some more  pathogenesis
specific treatment for diabetic neuropathy becomes
available in near future.
Dr. Vivian Fonseca, (Tulane University Health
Sciences Centre, Loussiana, U.S.A), discussed
about hypertension and diabetic nephropathy.
Hypertension is a very common problem in people
with diabetes. Hypertension is the cr i t ical
determinant of the development and progression of
diabetic nephropathy as well as CVD in diabetics.
The pathologic processes leading to glomerular
injury and proteinuria has been linked to advanced
glycation end products and imbalance in factors
affect ing vascular tone and structure. The
constrictors and growth promoters are angiotensin
II, catecholamines and endothelin (endothelium
derived constricting factors).  The dilators and growth
inhibitors could be nitric oxide, prostacyclin,
bradykinin and EDHF (endothel ium derived
hyperpolarizing factors).  The renin angiotension gets
activated with production of increased angiotensin
II which binds to AT1 and AT2 receptors resulting in
upregulation of gene expression of NF-Kappa B and
TGF result ing in a variety of lesions l ike
glomerulosclerosis, tubular interstitial fibrosis,
nephron loss and ul t imately renal fai lure.
Angiotensin II also induces oxidative stress on the
kidneys resulting in endothelial dysfunction and renal
injury.
The United Kingdom Prospective Diabetes Study
(UKPDS) has clearly shown the increased diabetes
related complications and mortality associated with
increased systolic blood pressure. Event rates for
select end points have markedly decreased with
good control of blood pressure.  The HOPE study,
Hypertension Optimal Tr ial  (HOT) and the
Appropriate Blood Pressure Control in Diabetes
(ABCD) trial have also shown the same results.  The
recommended BP in diabetic patients is less than
130/80 mmHg. As nephropathy is present at
diagnosis in 15 – 25% of patients, the annual
screening for microalbuminuria, tighter blood
pressure control <125 /75 (with ACE inhibitors, and
Angiotensin Receptor Blocker (ARB) as first choice),
better glycemic control with cessation of smoking
should be done. Use of ACE inhibitors and ARB’s is
advocated even for normotensive microalbuminuric
as microalbuminuria is associated with other
cardiovascular risk factors like insulin resistance,
lipid abnormalities, increased coagulatibility and
endothelial dysfunction.
The treatment strategies for advanced renal disease
are dietary modification (low protein and potassium
restr icted diet),  phosphate binders, calcium
maintainers like 1,25 Vit D, diuretics like metolazone
or frusemide for high BP or edema, potassium
monitoring and use of sodium bicarbonate for mild
acidosis.  Referral to a nephrologist should be
considered for serum creatinine of >2mg%.  For end
stage renal disease, transplant should be preferable
to dialysis, although the latter is also a viable
alternative.
Dr. Om. P.Ganda, (Joslin Diabetes Center,
Boston, U.S.A) discussed about “lipid subfractions
and their role in cardiovascular disease”. The
mystery of premature and accelerated process of
atherosclerosis in diabetes remains unsolved.  The
factors underlying accelerated atherogenesis in
diabetes are insulin resistance, diabetic dyslipidemia
and hyperglycemia causing damage through glyco-
oxidation, sorbitol / myoinositol pathway and
diacylglycerol / PKC activation, oxidative stress,
hemorrheological alterations like increased platelet
aggregat ion, increased f ibr inogen, reduced
fibrinolysis, increased PAI-1 and endothelial
dysfunction.
Stepwise selection of risk factors for coronary
artery disease in Type 2 diabetes in UKPDS study
have shown that high LDL cholesterol and low HDL
cholesterol are greater risk factors than HbA1c, blood
pressure and smoking. United Kingdom Prospective
Diabetes Study (UKPDS) has also shown that
elevated LDL cholesterol, low HDL cholesterol,
hypertension and hyperglycemia were identified as
the modifiable major risk factors.  Multiple mega trials
with HMG-COA reductase inhibitors (statins)
including 4S, CARE, LIPID, WOSCOPS, TEXCAPS/
AFCAPS and most recently, Heart Protection Study
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(HPS) has clearly established the benefits of LDL
cholesterol reduction in CVD outcomes (CAD and
stroke).  The subgroup analysis in most of these trials
revealed similar positive benefits in patients with
diabetes.
In diabetic patients, statins may not be able to
correct al l  the abnormalit ies of dyslipidemia
completely.  The abnormalities unique to diabetes
(particularly Type 2 diabetes mellitus) are increased
small dense LDL, increased triglyceride rich particles
(TGRP’s) including VLDL and remnant particles,
increased apo-B part ic les, low HDL and
glycooxidation products of various apo proteins.
Some studies suggest that apo-B or apo-B / apoA
ratios may be better predictors of CVD risk than LDL
cholesterol. The VA-HDL intervention Trial (VA-HIT)
and Diabetes Atherosclerosis Intervention Study
(DAIS) have shown the beneficial effects of fibrate
(fenofibrate) in delaying the disease progression in
a diabetic. The benefits and adverse effects of
combination therapy for dyslipidemia’s (adding niacin
or fibrate to a statin) should be always borne in mind.
The probable side effects could be increased risk of
myositis and hepatits (with niacin).  More studies are
needed for assessing the better outcome results with
combination therapy.
In his second lecture, Dr. F. Xavier Pi-sunyer,
spoke on the effective use of pharmacologic agents
to reduce body weight. Reduction in body weight has
been associated with reduced HbA1c levels in a
diabetic. Even a mild reduction of 1.9% in body
weight has been associated with a 0.4% reduction
in HbA1c, while a modest reduction of 10% body
weight reduces the HbA1c levels by 1.6%. Thus the
plan to reduce body weight should be formulated by:
a. Diet and exercise.
b. Drugs
c. Weight loss surgery
In U.S.A., anti-obesity drugs have been used at
BMI is >30 and at BMI of >27 if associated with
comorbidities like diabetes, hypertension and
coronary artery disease. The weight loss surgery is
being recommended at BMI of >40 and at BMI of
>35, if associated with comorbidities. The anti-obesity
drugs, if used should be continued till the results are
obtained.  At present two drugs available for long term
use are sibutramine and orlistat. Sibutramine (a
central ly act ing drug) is a serot inin and
norepinephrine reuptake inhibitor in postsynaptic
neurons which reduces food intake by enhancing
satiety. The effects of sibutramine on glucose and
lipid levels are related to weight loss. The usual
dosage is 10mg / day (once a day). Though with >15
mg/day – better weight  loss has been seen, the
drug’s usage is associated with increase in systolic
blood pressure (4-5 mmHg) and increased heart rate
(4-5 beats/min). The STORM trial has recommended
that blood pressure and the heart rate should be
monitored with sibutramine therapy. If BP is
increased by >6 mm of Hg or the heart rate is
increased by >4 beats / min, it is better to stop the
drug. The other antiobesity drug is Orlistat which acts
locally at G.I. tract. It competes with pancreatic lipase
thus blocking the triglyceride breakdown and causes
fat malabsorption.  Fat absorption is reduced by 30%
with Orlistat causing the weight loss. The drug should
be given 3 times daily with meals. As it also block
absorption of fat soluble vitamins, vitamin supplements
are necessary. The side effects due to fat malabsorption
are fecal urgency, fatty oily stools, flatus and oily
evacuation with increased defecation.  The GI side
effects of Orlistat can be reduced by use of Psyllium
with Orlistat. Apart from weight reduction, Orlistat also
reduces LDL cholesterol by 16%.
Dr. Martha Funnel, in her second lecture talked
about opt imal strategies for diabetes self
management education. Self management education
continues to be an integral component of care for
diabet ic pat ients. Though there is a lot  of
improvement in diabetes care, there still exists a gap
between promise and real i ty.  Diabetes self
management education is the key to closing that gap.
In order to be effective, diabetes self management
education must be evidence based, practical, pro-
active and collaborative. The future of diabetes self-
management education depends on follow-up to
sustain effects, integrate diabetes self management
education into ongoing care, expand use and training
of health professionals, expand outcome evaluation
(costs, quality of life, long term outcomes) and to
expand international efforts to promote quality
diabetes self-management education.
In his second lecture ,  Dr. Om P.Ganda,
discussed about the current status of management
of diabet ic dysl ipidemia. The current
recommendations for management of diabetic
dyslipidemia are primarily based on the NCEP expert
panel and  ATP III reports. The goals in diabetic
patients for lipids are:
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i. target primarily LDL cholesterol
ii. As diabetes is a risk factor for coronary heart
disease, the LDL cholesterol goal should be <100
mg%.
iii. The therapeutic options are
a. If LDL cholesterol is 100 – 129 mg%, increase
therapeutic life style changes; if uncontrolled,
add drugs (statin / fibrate / niacin) to modify
atherogenic dyslipidemia.
b. If LDL cholesterol is ≥ 130 mg%, simultaneously
initiate therapeutic lifestyle changes and LDL
cholesterol lowering drugs.
iv. After LDL cholesterol goal is met, if triglyceride is
≥ 200 mg%, non HDL cholesterol <130mg%,
becomes the target.
v. Target triglycerides <150mg%.
The therapeutic life style modification for patient
with diabetic dyslipidemia is weight reduction,
physical activity and dietary modifications. Total fat
should not exceed 25-30% of the total daily calorie
intake. Other therapeutic dietary options include plant
stanol / sterol (2mg/day), but they should not be given
below the age of 25 years. Larger doses of fish oil
should not be prescribed as they can worsen the beta
cell function.
In the Heart Protection Study simvastatin v/s
placebo was tried and it was clearly shown that a
40mg% reduction in LDL cholesterol resulted in 25%
reduction in CHD, stroke, and other cardiovascular
disease outcomes even if the baseline LDL cholesterol
was <100 mg/dl. No significant side effects were
observed.  This trial provides evidence that statins
have other beneficial  effects on endothel ial
dysfunction, vessel wall inflammation, plaque stability
etc. apart from their lipid lowering effects. Newer drugs
in the pipeline are ezitimibe, a cholesterol absorption
inhibitor and reovastatin, which can further help in
management of diabetic dyslipidemia.
Dr. David L. Horwitz (Life Scan Inc., U.S.A)
spoke about current and future trends in self
monitoring of blood glucose.  The advancements in
the area of self monitoring of blood glucose are:
a. Newer technologies wherein blood samples can
be obtained from other than fingertips (alternative
site testing – AST).
b. Continuous monitoring of blood glucose.
c. Non-invasive methods for glucose monitoring.
Alternative site testing like (arm and thigh) is made
possible by systems that can test very small blood
volumes (less than 2.5 microlitre). Available data
indicate that AST is useful prior to meals, but not
within 2 hours following meals, exercise or insulin
injection. With increasing insulin doses and intensive
therapy, blood sugar values related to meals and other
events must be stored in a data box. Modern data
processing and storage technologies offer the
potential for summarization and display of large
amounts of data in a form that may facilitate use of
the data to monitor diabetes management.
Continuous glucose monitoring system is now
widely being used as an adjunct to traditional self-
monitoring of blood glucose (SMBG).  It allows
recognition of patterns of glycemic excursions that
may not be evident when only a few measurements
are made in a day, thus offering a better glycemic
controls by understanding the real changes in blood
glucose levels. Non-invasive techniques like gluco-
watch are now available which measure interstitial
fluid glucose through reverse iontophoresis.  It should
be remembered that interstitial fluid glucose value
monitored by CGMS and gluco-watch lags blood
glucose value by few minutes and while dose
adjustments are made this fact should be kept in
mind.
In his second lecture, Dr. Vivian Fonseca,
discussed about the management of diabetic patients
with multiple co-morbidities. Management of patients
with multiple advanced complications can be
extremely difficult. Diabetes complications themselves
have an impact on the diabetes management, as the
natural history of the disease has advanced to a stage
of poor pancreatic function and severe insulin
resistance leading to decreased efficacy of oral
medications.  Diabetic Nephropathy, Neuropathy,
Retinopathy and the cardiovascular diseases are
extremely common complications particularly in Type
2 diabetic patients.
The guidelines for the management of Diabetic
Nephropathy are treatment of anemia by weekly
subcutaneous erythropoetin injections, aggressive
treatment of lipids & blood pressure, screening for
cardiovascular disease, routine eye checkups and
follow ups, dietary modifications (low protein, low
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cholesterol , low potassium), maintenance of serum
calcium and phosphorus levels and use of diuretics.
Diabetic neuropathy is the commonest complication
of diabetes and can result in amputations and
autonomic disturbances. Use of proper foot wear and
taking good care of feet and maintaining good
glycemic control can help to prevent amputations.
Diabetic retinopathy is a preventable complication
which can be detected early by fundus examination.
It can be treated by better glycemic control, better
blood pressure control, prevention of renal failure, and
cessation of smoking. In the future protein kinase - C
inhibitors may be of good treatment option.
Cardiovascular disease is an extremely common
complication particularly in Type 2 diabetes.  It has
been proved by the DIGAMI study that good glycemic
control at the time of myocardial infarction and
thereafter improves the prognosis. Insulin acts as an
anti-inflammatory agent apart from acting as anti-
hyperglycemic agents.  Aggressive management of
lipids, blood pressure are necessary in all the
diabetics with CAD. Thus in managing a complicated
diabetic patient,  a team of specialists is required
along with a Diabetologist.
In her second lecture, Dr. Lois Jovanovic, spoken
about management of Gestational Diabetes.
Gestatinal diabetes mellitus occurs when the
diabetogenic forces of normal pregnancy are not
counterbalanced by increased insulin secretion. The
“Diabetogenic Forces” include increased calorie
intake, increased adiposity, increased levels of
placental hormones : (HPL and Progesterone) and
maternal increase in Cortisol and Prolactin. BMI of >
24 kg/m2 increases the risk of diabetes in women,
8% of pregnant population is having GDM. The
prevalence of congenital malformations in a Type 1
pregnancy is 9% and that in type 2 pregnancies is
12%. With better glycemic control, the risk of
congenital malformations can be significantly reduced.
The fourth international workshop on GDM has
issued guidelines for screening.  Random Blood Sugar
should be checked after 50 grams glucose load and
if values are <140mg%, no further testing is needed.
If values are >140mg%, glucose tolerance testing
should be done with 100grams glucose load to
diagnose GDM. Screening test should be done at first
trimester and subsequent tests should be done at
the second and third trimesters. The usual prevalence
of macrosomia is 18% in uncontrolled diabetes
mellitus, which can be brought down to 7% with good
glycemic control. Even the frequency of caesarian
section is reduced to 7%. The 1 hour post meal
capillary blood glucose predicts the macrosomia best.
In the third trimester, peak value of 110mg% is
accepted.  In a baby born to a mother with
uncontrolled diabetes, the visceral fat deposition is
increased even at the time of birth. Pregnancy
potentates the dawn phenomenon by increasing the
hypercortisolemia, and hence the carbohydrate
content of breakfast should be <33%. The euglycemic
diet in pregnancy includes 30 kal/kg/day with a 40%
carbohydrates diet. The meals size should be small
and taken at frequent intervals to minimize the
postprandial rise in blood sugar levels.
Exercise causes uterine contraction and causes
fetal distress. Walking is permissible as it does not
cause heart rate variability. Arm exercises can be
allowed, as it helps in blood sugar stabilization and
at the same time does not cause fetal heart distress.
Oral hypoglycemic agents should not be used as they
can cross the placental barrier and cause neonatal
hypoglycemia and also increase the risk of congenital
malformations. The glycemic control should be
achieved by insulin / short acting insulin analogues.
The aim of the management is to control the
hyperglycemic peaks as it is important to reduce
macrosomia and other complicat ions during
pregnancy.  Thus, with a normal maternal blood
glucose levels (i.e. pre prandial of <90mg% and 1
hour post prandial of <120mg%), a normal outcome
is possible.
In his second lecture, Dr. John Buse, discussed
about intensive management of type 2 diabetes.
Patients with higher levels of blood glucose (i.e. fasting
plasma glucose >200mg%), almost always require
agents to increase insulin levels. When two drug
therapies are inadequate, the issue arises whether
multiple oral agents therapy is reasonable or whether
the use of insulin is indicated as a matter of routine.
Intensive management strategy aims at increasing
insulin sensitization by diet exercise, glitazones and
metformin. This regime minimizes the risk of
hyperglycemia and weight gain. If the blood sugars
are still not in the desired range, a secretagogue may
be added (either sulphonylurea or glinides). When the
glycemic control is still inadequate, insulin is needed.
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The principle of combination therapy of insulin and
OHA is to continue OHA as usual and add a single,
evening dose of insulin and try to control the FPG in
the reasonable range. This addition is limited by
hypoglycemia (mid sleep, AM and pre-lunch) and
weight gain. If even with this regime, the blood sugar
are not control led then to achieve a normal
postprandial glucose value, pre-meal soluble insulin
is added. Many type 2 diabetics patients eventually
require more than twice daily injections. In this case,
split mix insulins, multiple injections or even insulin
pump therapy can be used. With the availability of
insulin sensitizers and the availability of both long
acting (glargine) and rapid acting insulin analogs
(lispro), it appears that the majority of patients with
Type 2 diabetes can achieve the same levels of
glycemic control as laid down by the ADA.
Dr.Richard Kahn  (American Diabetes
Association, U.S.A) discussed about Diabetes Care
in America over the last decade. Many studies like
Diabetes Control and Complications Trial (DCCT)
and United Kingdom Prospective Diabetes Study
(UKPDS) have shown that improved diabetes care
will greatly reduce the morbidity and mortality
associated with diabetes. In addition, a wide variety
of pharmaceutical agents that are effective in
lowering blood glucose and blood pressure and in
adjusting abnormal lipid levels are available. In
addition, patients with diabetes have been given
substantial information on proper diabetes self
management.
Despite all these efforts and tools, performance
rates in the United States on process measures (e.g.
eye exam, lipids & HbA1c testing), and outcome
measures (eg.HbA1c, LDL-C, blood pressure levels)
remain far from optimal. An analysis of the factors
involved in achieving quality medical care reveals that
patient characteristics such as age, duration of
diabetes, educational level and care affected the
results far more than the physician’s knowledge and
skill. Attempts to change patient behaviour will be
essential in order to achieve optimal diabetes care
end results.
In addition, to the above lectures, there were 14
Meet the Professor Sessions on topics such as type
2 diabetes in children and youth, insulin resistance,
economic burden of diabetes, diabetic foot, diabetic
retinopathy and nephropathy, autonomic neuropathy,
intrauterine factors and development of diabetes,
combinat ion therapy of insul in and OHA,
hypoglycemia, endothelial dysfunction, glucotoxicity
and lipotoxicity, sexual dysfunction in diabetes,
postprandial hyperglycemia and is cure of diabetes a
reality. During these Meet the Professor Sessions,
eminent Indian Diabetologist teamed up with US
faculty and discussed these topics threadbare with a
lot of audience participations.
